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Editorial 
 
Research on measles virology, epidemiology, vaccine and vaccination strategies has expanded in recent years. Measles mortality reduction has 
already contributed significantly to progress towards the achievement of the 4
th Millennium Development Goal to reduce under 5 mortality by two 
thirds by 2015 compared with 1990 levels [1]. Interest in measles has increased with the increasing number of WHO regions (currently 5 out of 6, 
all except Southeast Asia) which have set time-limited goals to move from regional measles mortality reduction to the regional elimination of 
indigenous transmission. Indeed, the WHO Executive Board has requested studies on the feasibility of global measles eradication as a first step 
towards the possible establishment of a global goal [2]. 
 
Despite the abundance of research, there are a number of unanswered questions as we move towards a goal of measles elimination, many of 
which will be critical to achieving the elimination goal.   We present here a list of research priorities from a programmatic and operational 
perspective. 
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Measles epidemiology 
 
In certain settings, susceptible adolescents and young adults have played a significant role in measles outbreaks [3]. Therefore, will the 
achievement of measles elimination require greater attention to immunizing susceptible adolescents and young adults? Are older susceptibles more 
or less significant in urban, rural or highly isolated settings? 
 
WHO recommends that, where possible, HIV-positive infants and infants born to HIV-positive mothers should receive a measles dose at 6 months 
of age, in addition to the routine dose administered at 9 months of age [1]. Furthermore, in countries where an increasing number of HIV-positive 
children now receive anti-retroviral treatment and survive into adulthood, it is likely that secondary measles vaccine failure will begin to create 
significant new pools of susceptibles. In theory, the epidemiology of measles could alter in the absence of natural boosting by wild measles virus in 
highly vaccinated populations in the years following regional elimination and prior to global eradication (if that will eventually be achieved). If 
waning immunity is suspected in immunized populations, it will be necessary to verify immunity status through occasional sero-surveys. If waning 
immunity is indeed detected, will adolescent or adult booster doses of measles vaccines be indicated? 
 
As measles transmission declines generally, the relative importance of nosocomial measles transmission will increase, and several nosocomial 
outbreaks have been identified in the past decade [4,5]. WHO guidelines for the prevention and control of nosocomial measles were established 
some years ago [6], but are not systematically implemented in many countries. Therefore, should greater emphasis be placed on vaccinating all 
infants attending out-patient clinics or admitted to hospital in communities where measles is circulating or where measles is considered likely to 
spread from neighbouring communities? 
 
Measles surveillance 
 
Experience from other vaccine-preventable disease initiatives has shown that the establishment of case-based, laboratory-based surveillance is 
essential as we move from disease control to elimination.  Therefore, what are the critical surveillance indicators for measuring progress toward 
elimination and maintenance of elimination?  What is the sensitivity and specificity of the proposed set of the “elimination certification” criteria and 
of each criterion alone? Is it epidemiologically useful and cost-effective to continue conducting extensive genetic characterization of vaccine 
viruses? Are there benefits to be reaped from showing a declining number of genetic lineages? 
 
WHO currently recommends the use of measles IgM serology for case confirmation in surveillance in countries that adopt measles mortality 
reduction or elimination goals [8]. However, in recent years, alternative methods measuring measles IgG in dried blood-spots and oral fluid with 
improved sensitivity and specificity have become available that have demonstrated value for establishing population immunity to measles have 
become available [9]. These approaches are more acceptable because they avoid the need for venipuncture. The costs of specimen collection and 
laboratory assays for serum specimens, dried blood-spots and oral fluid are currently roughly similar [10]. Would it be operationally simpler to 
switch to oral fluid specimens for laboratory confirmation of measles? 
 
Vaccination strategies 
 
We know that in developing countries where the first dose of measles vaccine is administered to infants <12 months of age, a second dose is 
required to eliminate susceptibles from the population and interrupt measles transmission [11]. Under field conditions, what levels of 1
st and 2
nd 
dose vaccination coverage will interrupt measles transmission? 
 
In most developing countries, the 2nd measles dose is currently delivered through a mass campaign strategy that is repeated when a critical mass 
of new susceptibles is estimated to have entered the population [11]. Current practice is to space measles campaigns at intervals of three years. 
Can the current method for estimating the interval [12] be improved upon? 
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Furthermore, what is the ideal age, from both the epidemiological and operational perspectives, for the administration of the 2
nd dose? In the 
Mideast, the second routine dose is more often given on school entry than in the second year of life. Is this policy more widely applicable? 
 
Increasingly, developing countries are considering delivering the 2
nd measles dose through the routine immunization programme, for operational 
convenience.  Are the same levels of 1
st and 2
nd dose vaccination coverage required to interrupt measles transmission, regardless of the delivery 
strategy adopted for the 2
nd dose?   
 
Does measles vaccination coverage increase or decrease when mass measles campaigns are integrated with the delivery of other public health 
i n t e r v e n t i o n s  s u c h  a s  i n s e c t i c i d e  T r e a t e d  n e t s  ( I T N )  d i s t r i b u t i o n  o r  w i t h  o t h e r  c o n t a c t s  w i t h  e l i g i b l e  c h i l d r e n  s u c h  a s  C h i l d  H ealth Days? In 
particular, what are the possible advantages of giving measles vaccination at the same time as malaria bednet distribution? 
 
Can very large countries, such as Nigeria, Indonesia, China and India, follow the same strategy as other countries, in particular simultaneous 
nationwide campaigns? Vaccinating 50 to 100 million children in a single week presents special challenges, both from the operational and from the 
vaccine supply standpoints. 
 
The PAHO model for integrated measles and rubella elimination is applicable only where countries adopt the PAHO objective of regional rubella 
elimination. When countries introduce rubella vaccination, either for control or, as in the Americas, for elimination, what is the best approach to 
harmonizing approaches to rubella and measles vaccination?  
 
The house-to-house approach is fundamental to polio eradication, but not, at present, to measles.  Can countries with weak health infrastructures 
interrupt measles transmission without such practices as preregistration of vaccinees and house-to-house mobilization?  
 
Alternative vaccine delivery technologies 
 
What are the possible policy changes if needleless measles vaccine, given as an aerosol, is licensed and commercialized? Will measles campaign 
approaches more closely resemble the door-to-door approach of polio campaigns? In the event that India, for example, licensed needleless 
technology, what field studies would be needed to fit the new technology into the existing strategies? 
 
Co-administration of measles vaccine with other vaccines 
 
How does the co-administration measles vaccine with other vaccines (e.g., yellow fever, Japanese encephalitis, tetanus toxoid, etc...) affect 
vaccine safety and immunogenicity? 
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